Clinical trial
A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day
NCT00496483 is registered in ClinicalTrials.gov with Veloxis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day
- Lead sponsor
- Veloxis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- March 31, 2008
- Enrollment
- 60 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
renal failure